Supplements

Sotatercept improves hemodynamics, right heart function, and reduces the risk of adverse clinical outcomes in PAH patients not achieving low risk on background therapy

In recent randomized trials, add-on therapy with sotatercept led to improvements in hemodynamics and right heart function, and reduced the risk of adverse clinical outcomes in patients with pulmonary arterial hypertension who were not achieving low risk on maximal background therapy. This represents the first antiremodeling therapy approved for PAH, targeting dysregulation of the activin arm of the TGF-β pathway.

Last updated: Jul 15, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score42/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.

observational

Humbert M, Zeder K, Kovacs G, Weatherald J · Circulation (2026)

Participants: N/A
Duration: N/A
Intervention: Add-on therapy with sotatercept
Outcome: Hemodynamics, right heart function, risk of adverse clinical outcomes
Effect Size: N/A
Population: Patients with pulmonary arterial hypertension not achieving low risk on maximal background therapy

Result:

PubMed: 42441757DOI: 10.1161/CIRCULATIONAHA.126.079274

Mechanism Graph

Dysregulation of the activin arm of the TGF-β pathway drives vascular remodeling in PAH
↓
Sotatercept targets this activin/TGF-β pathway dysregulation
↓
Sotatercept inhibits aberrant signaling to reverse fibroproliferative vascular remodeling
↓
Improved hemodynamics, right heart function, and reduced adverse clinical outcomes

Limitations

  • ⚠Abstract does not provide specific effect sizes, sample sizes, or exact trial durations
  • ⚠Long-term safety and efficacy beyond the trial periods are not addressed in this abstract
  • ⚠Generalizability to PAH subtypes (e.g., methamphetamine-associated, schistosomiasis-associated) is unclear

Frequently Asked Questions

What is sotatercept and how does it work in PAH?▼

Sotatercept is the first antiremodeling therapy approved for PAH. It targets dysregulation of the activin arm of the TGF-β pathway, which is a critical driver of vascular remodeling in the disease.

Who is eligible for sotatercept treatment?▼

Sotatercept is indicated as add-on therapy for patients with PAH who are not achieving low risk despite maximal background therapy, including combination oral medications or parenteral prostacyclin.

What outcomes did sotatercept improve in clinical trials?▼

Recent randomized trials showed that sotatercept improved hemodynamics, right heart function, and reduced the risk of adverse clinical outcomes in PAH patients.

Is sotatercept a cure for PAH?▼

No, sotatercept is an add-on therapy that improves outcomes but does not cure PAH. Lung transplantation remains an important option for patients who remain at higher risk despite maximal therapy.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Humbert M, Zeder K, Kovacs G, Weatherald J. "Transforming Pulmonary Arterial Hypertension: Key Milestones and Future Perspectives.." Circulation, 2026. PMID: 42441757 DOI: 10.1161/CIRCULATIONAHA.126.079274
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.